A5021918346- Food Allergy and Anaphylaxis Research
- Monoclonal and Polyclonal Antibodies Research
- Asthma and respiratory diseases
- Dermatology and Skin Diseases
- Urticaria and Related Conditions
- Transgenic Plants and Applications
- HER2/EGFR in Cancer Research
- Allergic Rhinitis and Sensitization
- Biotin and Related Studies
Janssen (United States)
2023-2024
Food allergy is caused by allergen-specific immunoglobulin E (IgE) antibodies, but little known about the B cell memory of persistent IgE responses. Here, we describe, in human pediatric peanut allergy, a population CD23 + IgG1 cells arising type 2 immune responses that contain high-affinity peanut-specific clones and generate IgE-producing upon activation. The frequency correlated with circulating concentrations children allergy. A corresponding “type 2–marked” was identified single-cell...
Abstract Food allergy is caused by allergen-specific IgE antibodies but little known about the B cell memory of persistent responses. Here we describe in human pediatric peanut CD23 + IgG1 cells arising type 2 responses that contain specific clones and generate on activation. These ‘type2-marked’ differentially express IL-4/IL-13 regulated genes FCER2 / CD23, IL4R , germline IGHE carry highly mutated receptors (BCRs). Further, high affinity for main allergen Ara h mapped to population...
Abstract Bermekimab is a human-derived recombinant monoclonal antibody that exhibits immunoregulatory activity by specifically blocking interleukin-1α activity. Four phase 2 studies evaluated efficacy and safety of bermekimab in patients with moderate-to-severe atopic dermatitis (AD). In addition, novel human skin explant model was developed to assess pharmacokinetics/pharmacodynamics proteomic/transcriptomic effects. Study 1 (NCT03496974, N = 38) an open-label, dose escalation study...